SOX2 has been identified as a tumor-associated antigen in the patients with both LSCC (Dhodapkar et al., 2013) and glioma (Schmitz et al., 2007), where SOX2-specific T cell immune responses are mounted against SOX2 and this phenomenon results in tumor regression. The gene discussed is SOX2; the disease is central nervous system cancer.